- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03059264
Trial Readiness and Endpoint Assessment in Congenital Myotonic Dystrophy (TREAT-CDM)
Congenital Myotonic Dystrophy (CDM) is a multi-systemic, dominantly inherited disorder caused by a trinucleotide repeat expansion (CTGn) in the DMPK gene. CDM occurs when the CTGn increases between the adult myotonic dystrophy type-1 (DM1) parent and the child. Children with CDM present at birth with respiratory insufficiency, talipes equinovarus, feeding difficulties and hypotonia. There is a 30% mortality rate in the first year of life. As children grow, they are at risk for intellectual impairment, autistic features, gastrointestinal symptoms, and motor delay.
The investigators will enroll children with CDM between ages 0-15 with visits at baseline and one year to evaluate appropriate physical functional outcomes, cognitive function and quality of life over time. Functional outcome measures will be correlated with potential biomarkers in the children. Completion of these specific aims will extend the understanding of disease progression in CDM and will provide the requisite information for successful therapeutic trials in children with DM.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Ruby Langeslay, MD
- Phone Number: 804-828-8481
- Email: ruby.langeslay@vcuhealth.org
Study Contact Backup
- Name: Jennifer Raymond
- Phone Number: 804-828-6318
- Email: jennifer.raymond@vcuhealth.org
Study Locations
-
-
Ontario
-
London, Ontario, Canada
- Completed
- Pediatric Neuromuscular Research, Children's Hospital - LHSC
-
-
-
-
-
Milano, Italy, 20162
- Recruiting
- Centro Clinico NeMO
-
Contact:
- Alessandra Di Bari
- Email: alessandra.dibari@centrocliniconemo.it
-
Contact:
- Luca Mauro
- Email: luca.mauro@centrocliniconemo.it
-
Principal Investigator:
- Valeria Sansone, MD
-
-
-
-
Virginia
-
Richmond, Virginia, United States, 23298
- Recruiting
- Virginia Commonwealth University
-
Contact:
- Jodie Howell, LPN
- Phone Number: 804-592-1859
- Email: jodie.howell@vcuhealth.org
-
Principal Investigator:
- Nicholas E Johnson, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
CDM Group
Inclusion Criteria:
- Age 0-15 yrs
- Diagnosis of CDM, based on symptoms and genetic testing of expanded trinucleotide repeats.
Exclusion Criteria:
- Any other non-DM1 illness that would interfere with the ability or results of the study in the opinion of site investigator
- Significant trauma within one month
- Internal metal or devices
Control Group
Inclusion Criteria:
- Age 0-15 yrs
- Healthy children on no medication
Exclusion Criteria:
- Any illness or situation that, in the opinion of the site investigator, has the possibility to interfere with study procedures
- DM type 1 and 2
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
CDM
Children with Congenital Myotonic Dystrophy
|
Longitudinal disease progression
|
Control
Healthy Children
|
Longitudinal disease progression
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Grip Strength
Time Frame: 1 year
|
Measure of force generated by hand grip
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Congenital and Childhood Onset Myotonic Dystrophy Health Index (CCMDHI)
Time Frame: 1 year
|
Disease specific patient and parent reported outcome measure of quality of life
|
1 year
|
6-minute walk
Time Frame: 1 year
|
Assess distance walked over 6 minutes as a sub-maximal test of aerobic capacity/endurance
|
1 year
|
Behavior Rating Inventory of Executive Function (BRIEF)
Time Frame: 1 year
|
An 86-item parent/caregiver-proxy and teacher-proxy rating form of executive function skills in every-day settings such as school, home, and social situations
|
1 year
|
Lip Force
Time Frame: 1 year
|
Measure of force generation by orbicularis oris
|
1 year
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Nicholas Johnson, MD, Virginia Commonwealth University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HM20014211
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Congenital Myotonic Dystrophy
-
Myotonic Dystrophy FoundationRecruitingMyotonic Dystrophy | Myotonic Dystrophy 1 | Steinert's Disease | Congenital Myotonic Dystrophy | PROMM (Proximal Myotonic Myopathy) | Steinert Disease | Dystrophia Myotonica 1 | Myotonic Dystrophy 2 | Dystrophia Myotonica | Dystrophia Myotonica 2 | Myotonia Dystrophica | Myotonic Dystrophy, Congenital | Myotonic... and other conditionsUnited States
-
University of RochesterNational Institute of Neurological Disorders and Stroke (NINDS)RecruitingMuscular Dystrophy | Myotonic Dystrophy Type 2 | Myotonic Dystrophy Type 1 | Myotonic Dystrophy | Facioscapulohumeral Muscular Dystrophy | Steinert's Disease | Congenital Myotonic Dystrophy | PROMM (Proximal Myotonic Myopathy) | Myotonic Muscular DystrophyUnited States
-
Avidity Biosciences, Inc.CompletedMyotonic Dystrophy | Myotonic Disorders | Myotonic Dystrophy Type 1 (DM1) | Myotonic Dystrophy 1 | Myotonic Muscular Dystrophy | DM1 | Dystrophy Myotonic | Steinert DiseaseUnited States
-
Virginia Commonwealth UniversityRecruitingCongenital Myotonic Dystrophy | Childhood Myotonic Dystrophy | CDM | CHDMUnited States, Italy
-
National Institute of Neurological Disorders and...TerminatedMyotonic Dystrophy Type-1 | Myotonic Dystrophy Type-2United States
-
AMO Pharma LimitedCompletedCongenital Myotonic DystrophyUnited States, Canada, New Zealand, Australia, United Kingdom
-
AMO Pharma LimitedRecruitingCongenital Myotonic DystrophyUnited States, Canada, Australia, New Zealand
-
McMaster UniversityCompletedMuscular Dystrophies | Myotonic Dystrophy 1Canada
-
PepGen IncRecruitingMyotonic Dystrophy 1United States, Canada
-
Norwegian School of Sport SciencesUniversity of Oslo; Oslo University Hospital; University of Copenhagen; University... and other collaboratorsCompleted
Clinical Trials on Natural history
-
Universitätsklinikum Hamburg-EppendorfRecruitingBatten Disease | Neuronal Ceroid Lipofuscinosis | CLN1 Disease | CLN2 Disease | CLN3 Disease | CLN4 Disease | CLN5 Disease | CLN6 Disease | CLN7 Disease | CLN8 Disease | CLN10 Disease | CLN11 Disease | CLN12 Disease | CLN13 Disease | CLN14 DiseaseGermany
-
Monash UniversityChildren's Hospital of Philadelphia; McGill University; University of Florida; University... and other collaboratorsActive, not recruitingFriedreich AtaxiaUnited States, Canada, Australia, Brazil, Germany
-
LYSOGENECasimir, LLC; Cure GM1 FoundationCompleted
-
Emily de los ReyesRecruitingBatten Disease | CLN6United States
-
Ludwig-Maximilians - University of MunichCompletedInclusion Body Myositis, Sporadic | Inclusion Body Myopathy, Autosomal-recessive | Inclusion Body Myopathy, Autosomal-dominant | Congenital Cataracts, Facial Dysmorphism, And NeuropathyGermany
-
Akouos, Inc.Eli Lilly and CompanyRecruitingSensorineural Hearing Loss, BilateralUnited States, Taiwan, Germany, Spain, Australia, United Kingdom
-
InnoskelRecruitingSEDC | Hypochondrogenesis | Semd, Strudwick Type | Kniest DysplasiaFrance, Spain
-
Istituto Auxologico ItalianoUniversity of Turin, ItalyRecruiting
-
Columbia UniversityNational Eye Institute (NEI); Centre Hospitalier National d'Ophtalmologie des... and other collaboratorsRecruitingRetinitis Pigmentosa | Best Vitelliform Macular DystrophyUnited States, Germany, France
-
Institute of Molecular and Clinical Ophthalmology...Boehringer IngelheimActive, not recruitingAge-Related Macular Degeneration | Geographic Atrophy | Visual Field Defect, Central Scotoma of Both EyesSwitzerland